Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (397)	9/4/2001 1:46:43 AM
From: scaram(o)uche	Read Replies (1) of 1005

The results look pretty good to me. Obviously, Topol is in their camp. A desired effect doesn't formally reach statistical significance, but "there was not a significant increase in the incidence" of bleeds. How would it sound like this?........ "the increase in intra-cranial hemorrhage ass'd with ANGIOMAX-based treatment did not reach conventional levels of statistical significance." Not as good, huh? How does this sound?........ "there was not a significant decrease in risk of death." Not as good, again? But......... looks good to me.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next